| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
46 |
| Employees |
1,000 |
| Revenues (TTM) (Millions $) |
1,074 |
| Net Income (TTM) (Millions $) |
267 |
| Cash Flow (TTM) (Millions $) |
-109 |
| Capital Exp. (TTM) (Millions $) |
35 |
Business Description
Company Overview: Abiomed Inc.
Abiomed Inc. is a prominent medical device company that specializes in developing and manufacturing products aimed at supporting and enhancing the pumping function of the heart. The companys primary product, the Impella heart pump, is a groundbreaking device that offers temporary circulatory support during high-risk medical procedures such as heart transplants, angioplasties, and stent placements.
History and Headquarters:
Founded in 1981, Abiomed is headquartered in Danvers, Massachusetts, and boasts additional locations in Germany, Japan, and Switzerland. The company has maintained a clear focus on innovation, striving to improve patient outcomes and reduce healthcare costs through cutting-edge medical technology.
Flagship Product: Impella Heart Pump
The Impella heart pump represents Abiomeds flagship innovation, providing a minimally invasive alternative to traditional heart surgery. The device is inserted through a small incision in the groin and carefully threaded up to the heart to support it during critical procedures. Notably, the Impella is recognized as the only FDA-approved temporary heart pump designed for high-risk patients suffering from advanced heart failure or undergoing complex cardiac procedures.
Additional Products:
In addition to the Impella, Abiomed has expanded its product offerings to include the Breethe OXY-1 System, a portable oxygenation and ventilation system specifically designed for patients experiencing acute respiratory failure. This diversification reflects the companys commitment to address a broad range of critical medical needs.
Education and Training:
Abiomed emphasizes the importance of education and training for healthcare professionals. The company has developed extensive programs to ensure that practitioners are knowledgeable about their products and capable of utilizing them effectively, enhancing patient care and safety.
Financial Performance:
Abiomed has demonstrated consistent growth, reporting annual revenues exceeding $800 million in 2021. The company employs over 1,500 individuals, signifying its status as a significant player within the medical device industry. Abiomeds stock is publicly traded on the NASDAQ under the ticker symbol ABMD.
Commitment to Innovation and Patient Care:
The company is deeply committed to patient care and innovation. Abiomed actively collaborates with healthcare professionals and organizations to ensure the safe and effective use of its products, continually striving to improve patient outcomes and reduce overall healthcare costs.
Through its focus on developing new technologies and fostering partnerships in the medical community, Abiomed remains dedicated to enhancing the quality of care provided to patients worldwide.
Company Address: 22 CHERRY HILL DRIVE Danvers 1923 MA
Company Phone Number: 646-1400 Stock Exchange / Ticker: NASDAQ ABMD
|
%
1.83%